A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.

Phase 2

• Conditions: advanced gastric cancer

• Registration Number: JPRN-UMIN000000801
• Lead Sponsor: Dept. of Internal Medicine(4)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-08-15
• Study Completion: 2011-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1. A history of hypersensitivity reaction to drugs formulated with polysorbate 80. 2. Patients contraindicated to docetaxel, cisplatin, S-1, or G-CSF. 3. Documented or suspected infection. 4. Uncontrolled medical conditions (e.g., malignant hypertension, congestive heart failure, myocardial infarction in previous 3 months, arrhythmia requiring treatment, diabetes, interstitial pneumonia, pulmonary fibrosis). 5. Grade 2 or greater peripheral neuropathy. 6. Patients with brain metastasis 7. Patients with diarrhea. 8. Active concomitant malignancy. 9. Pregnant or lactating women and women of child bearing potential not using contraception. 10. Men with partner willing to get pregnant 11. Patients judged by the investigator as unfit to be enrolled in the study. 12. Patients already enrolled in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified